← Leaderboards
Xiaotu Ma
St. Jude Children'S Research Hospital
$1,672,253
Attributed
$1,672,253
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $444.3K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,672,253 · 1
By mechanism
R01$1,672,253 · 1
Top collaborators
No co-investigators on record.
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Jun J. Yang$13,116,250
- Gregory Armstrong$61,807,544
- Pamela S Hinds$7,931,269
- Richard James Gilbertson$38,555,720
- Stephen X Skapek$24,951,237
Others in their field
Other Rising Stars on “Acute Lymphocytic Leukemia”
- Erin Marcotte · University Of Minnesota$4,498,384
- Martin Pule · University College London$3,627,871
- Saad J. Kenderian · Mayo Clinic Rochester$2,442,317
- Friederike Herbst-Nowrouzi · University Of Pennsylvania$2,137,320
- Ellen Van Der Plas · Arkansas Children'S Hospital Res Inst$2,055,804
- Nicholas Pannunzio · University Of California-Irvine$1,966,363
Research focus
Acute Lymphocytic LeukemiaAlgorithmsAffectBloodCancer CellCancer EtiologyCellsCessation Of LifeChemotherapyChildChildhood Acute Lymphocytic LeukemiaClinical ResearchClinical TrialsClinical Trials Cooperative GroupClustered Regularly Interspaced Short Palindromic RepeatsCodeCohortCollaborationsCoupledCytotoxic ChemotherapyDeep SequencingDesignDetectionDiagnosis
Grant awards (4)
Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia$416,011
R01 · FY2025 · CA · contact PI
Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia$395,211
R01 · FY2024 · CA · contact PI
Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia$416,766
R01 · FY2023 · CA · contact PI
Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia$444,265
R01 · FY2022 · CA · contact PI